- Aucune donnée
Français
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Superlight Photonics, a start-up company headquartered in Enshurd, has developed a broadband laser chip that can replace the bulky and power consuming technology currently used in advanced imaging and metering equipment.This idea suddenly appeared in his mind, while moving his other belongings from Germany to his new home in Enschede. During his doctoral research at the Max Planck Institute of Mul...
Recently, SuperLight Photonics, a leading laser technology manufacturer, announced that it has received strategic investment from global venture capital firm Hamamatsu Ventures, which will be used to promote long-term innovation and collaborative development of its laser technology. Hamamatsu Ventures focuses on investing in photonics companies that address future demand expectations, particular...
A Boston University research project has successfully developed an innovative single-cell sorting technique that uses stimulated Raman spectroscopy to replace traditional fluorescent labeling and achieve labeling free and non-destructive single-cell measurements. This technology is expected to have a profound impact in the fields of cytology, microbiology and biomedical research, allowing scienti...
Recently, Bitsensing, a leading provider of advanced radar solutions in South Korea, announced the successful completion of Series B financing, with a financing amount of up to $25 million (approximately RMB 181.6 million).This major investment is led by a series of well-known venture capital firms and strategic investors, which not only demonstrates Bitsensing's leading position in the radar tech...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...